Biofrontera AG (BFRA): Price and Financial Metrics

Biofrontera AG (BFRA)

Today's Latest Price: $8.23 USD

0.02 (0.24%)

Updated Jan 20 6:55pm

Add BFRA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BFRA Stock Summary

  • With a one year PEG ratio of 0.64, Biofrontera AG is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.04% of US stocks.
  • Of note is the ratio of Biofrontera AG's sales and general administrative expense to its total operating expenses; 98.58% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for Biofrontera AG comes in at 130.84%, a number that bests 95.54% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biofrontera AG are ANTE, UUU, TGEN, AFI, and TBLT.
  • BFRA's SEC filings can be seen here. And to visit Biofrontera AG's official web site, go to

BFRA Stock Price Chart Interactive Chart >

Price chart for BFRA

BFRA Price/Volume Stats

Current price $8.23 52-week high $55.00
Prev. close $8.21 52-week low $5.27
Day low $8.05 Volume 35,500
Day high $8.35 Avg. volume 129,967
50-day MA $7.28 Dividend yield N/A
200-day MA $8.29 Market Cap 196.48M

Biofrontera AG (BFRA) Company Bio

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Biofrontera AG was founded in 1997 and is based in Leverkusen, Germany.

BFRA Latest News Stream

Event/Time News Detail
Loading, please wait...

BFRA Latest Social Stream

Loading social stream, please wait...

View Full BFRA Social Stream

Latest BFRA News From Around the Web

Below are the latest news stories about Biofrontera AG that investors may wish to consider to help them evaluate BFRA as an investment opportunity.

Biofrontera announces preliminary revenue figures for the full year 2020

Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020. Biofrontera Group's preliminary unaudited revenue for the period January 1 to December 31, 2020 was in the range of EUR 30.3 million to EUR 30.6 million compared to EUR 31.3 million in 2019.Preliminary revenues from product sales in the US were around EUR 16.6 million, compared to EUR 23.3 million in 2019 (-29%). In Germany, revenues from product sales amounted to approximately EUR 5.2 million, compared to EUR 4.6 million in fiscal year 2019 (+13%). In the rest of Europe, the Company generated product sales of around EUR 2.1 million, compared ...

Yahoo | January 8, 2021

Cologne Higher Regional Court grants approval of capital increase

Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international…

GlobeNewswire | January 7, 2021

Actinic Keratosis Drugs Market Research Report (2020-2026): Key Trends and Opportunities |GALDERMA, LEO Pharma, Valeant, Biofrontera

The global Actinic Keratosis Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and

OpenPR | December 15, 2020

Dermatology Treatment Devices Market Is Expected To Reach US$ 8,800.07 Million In By 2027 With Cutera Inc.; Bausch Health Companies Inc.; Sciton, Inc.; Lumenis; Alma Lasers; Cynosure, Candela Corporation; Biofrontera Ag; Avita Medical; and PhotoMedex

The proposed Dermatology Treatment Devices Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes

OpenPR | November 25, 2020

Biofrontera AG to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 2:00 PM Eastern Time.

Yahoo | November 12, 2020

Read More 'BFRA' Stories Here

BFRA Price Returns

1-mo 18.42%
3-mo 10.77%
6-mo 28.39%
1-year N/A
3-year N/A
5-year N/A
YTD 12.89%
2020 N/A
2019 0.00%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7544 seconds.